Targeted Combinations May Reduce Cost By Shortening Treatment
Executive Summary
Using combinations of targeted oncologics may actually reduce the cost of treatment with the expensive cancer therapies by reducing the duration of treatment, Vanderbilt-Ingram Cancer Center's Carlos Arteaga suggested during ASCO's annual meeting in Atlanta
You may also be interested in...
Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients
Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16
Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients
Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16
Combo Therapy May Be Best Option For Kidney Cancer Patients, Sponsors
Developing combination regimens may provide optimal therapy for renal cell carcinoma patients and, simultaneously, allow manufacturers to avoid partitioning off the relatively limited kidney cancer market, Genentech VP-Clinical Oncology Gwen Fyfe suggested